| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |